1-(2-(2,2,2-Trifluoroethoxy)ethyl-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors
Authors:
- Michael B. TollefsonMTMichael B. Tollefson
- John K. WalkerJWJohn K. Walker
- Michael J. PalmerMPMichael J. Palmer
- 1 May 2010
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 20 (10) , 3125-3128
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: Discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-oneBioorganic & Medicinal Chemistry Letters, 2009
- Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitorsBioorganic & Medicinal Chemistry Letters, 2009
- Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring systemBioorganic & Medicinal Chemistry Letters, 2009
- Overcoming Undesirable hERG Potency of Chemokine Receptor Antagonists Using Baseline Lipophilicity RelationshipsJournal of Medicinal Chemistry, 2008
- The Role of PDE5-Inhibitors in Cardiopulmonary Disorders: From Basic Evidence to Clinical DevelopmentCurrent Medicinal Chemistry, 2007
- Design of Second Generation Phosphodiesterase 5 InhibitorsCurrent Topics in Medicinal Chemistry, 2007
- Phosphodiesterase 5 enzyme and its inhibitors: Update on pharmacological and therapeutical aspectsMethods and Findings in Experimental and Clinical Pharmacology, 2004
- Sildenafil in erectile dysfunction: a critical reviewCurrent Medical Research and Opinion, 2003